Tumor burden affects the progression pattern on the prognosis in patients treated with sorafenib

Area of Science:

• Hepatobiliary Oncology
• Cancer Progression Research
• Clinical Trial Design

Background:

• Tumor progression patterns influence survival in advanced hepatocellular carcinoma (HCC).
• Previous research on progression patterns and survival in HCC has yielded contradictory results.
• Understanding these patterns is crucial for clinical trial design and patient prognosis.

Purpose of the Study:

• To analyze the impact of different tumor progression patterns and tumor burden on HCC patient survival.
• To investigate the interaction between progression patterns and tumor burden in HCC.
• To provide insights for personalized treatment and clinical trial design in HCC.

Main Methods:

• Retrospective cohort study of 538 HCC patients treated with sorafenib and showing radiographic progression.
• Cox regression analysis incorporating an interaction term between progression pattern and tumor burden.
• Categorization of tumor burden into low, medium, and high subgroups using the six-and-twelve criteria.

Main Results:

• Patients with extrahepatic progression (NEH/EHG) exhibited significantly worse overall survival (OS) and post-progression survival (PPS) compared to those with intrahepatic progression (NIH/IHG).
• The hazard ratio for extrahepatic progression was highest at low tumor burden (HR 2.729) and decreased with increasing tumor burden.
• Specifically, OS for intrahepatic progression was 14.1/19.9 months vs. 9.3/9.2 months for extrahepatic progression; PPS was 8.1/13.1 months vs. 4.9/5.1 months.

Conclusions:

• The interaction between tumor progression patterns and tumor burden significantly impacts HCC patient prognosis.
• As tumor burden increases, the patient's risk of death becomes less sensitive to the specific progression pattern.
• These findings are valuable for optimizing personalized treatment strategies and refining clinical trial designs for HCC.